Nat Genet:转移性乳腺癌中雌激素受体编码基因或变异

2014-01-02 中国科学报 中国科学报

据《自然—遗传学》上的两项独立研究显示,在某些转移性乳腺癌病例中,负责编码雌激素受体的基因会发生变异。这意味着雌激素受体对抗药物或对某些转移性乳腺癌病例具有疗效。 Sarat Chandarlapaty等人选取了36个对激素疗法产生抗性的转移性乳腺癌肿瘤,对其中的230种基因进行测序,在9个肿瘤中发现ESR1基因突变。他们分析了44个转移性乳腺癌肿瘤中的ESR1基因,发现其中5个肿瘤存在基因突变

据《自然—遗传学》上的两项独立研究显示,在某些转移性乳腺癌病例中,负责编码雌激素受体的基因会发生变异。这意味着雌激素受体对抗药物或对某些转移性乳腺癌病例具有疗效。

Sarat Chandarlapaty等人选取了36个对激素疗法产生抗性的转移性乳腺癌肿瘤,对其中的230种基因进行测序,在9个肿瘤中发现ESR1基因突变。他们分析了44个转移性乳腺癌肿瘤中的ESR1基因,发现其中5个肿瘤存在基因突变。

在另一项研究中,Arul Chinnaiyan等人对11个肿瘤进行外显子组测序,在6个肿瘤中发现ESR1基因突变。两项研究都通过培养细胞展示了在缺少雌激素时变异雌激素受体的激活以及变异雌激素受体面对抗雌激素疗法的反应。

原文出处:

Weiyi Toy, Yang Shen, Helen Won,Bradley Green, Rita A Sakr, Marie Will, Zhiqiang Li, Kinisha Gala, Sean Fanning, Tari A King, Clifford Hudis, David Chen,Tetiana Taran, Gabriel Hortobagyi, Geoffrey Greene, Michael Berger,José Baselga & Sarat Chandarlapaty.ESR1 ligand-binding domain mutations in hormone-resistant breast cancer.Nature Genetics  03 November 2013 doi:10.1038/ng.2822

Dan R Robinson,Yi-Mi Wu,Pankaj Vats,Fengyun Su,Robert J Lonigro,Xuhong Cao,Shanker Kalyana-Sundaram,Rui Wang,Yu Ning,Lynda Hodges,Amy Gursky,Javed Siddiqui,Scott A Tomlins, Sameek Roychowdhury, Kenneth J Pienta,Scott Y Kim,J Scott Roberts,James M Rae,Catherine H Van Poznak,Daniel F Hayes, Rashmi Chugh, Lakshmi P Kunju,Moshe Talpaz, Anne F Schott & Arul M Chinnaiyan.Activating ESR1 mutations in hormone-resistant metastatic breast cancer.Nature Genetics 03 November 2013 doi:10.1038/ng.2823

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (10)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1805909, encodeId=02af180590904, content=<a href='/topic/show?id=c435e92536b' target=_blank style='color:#2F92EE;'>#编码基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79253, encryptionId=c435e92536b, topicName=编码基因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Tue Jun 03 12:43:00 CST 2014, time=2014-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879825, encodeId=c9c118e982504, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Jan 31 09:43:00 CST 2014, time=2014-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733668, encodeId=d0a51e3366847, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Thu Jun 05 23:43:00 CST 2014, time=2014-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685924, encodeId=7379168592419, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Tue Jan 14 20:43:00 CST 2014, time=2014-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048559, encodeId=e841204855970, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Mon Apr 07 15:43:00 CST 2014, time=2014-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=6536, encodeId=4717653690, content=如何临床应用呢, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Sat Jan 04 10:07:00 CST 2014, time=2014-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342290, encodeId=ff051342290e7, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Sat Jan 04 02:43:00 CST 2014, time=2014-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386107, encodeId=13dc138610ef4, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sat Jan 04 02:43:00 CST 2014, time=2014-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503469, encodeId=7bb31503469b0, content=<a href='/topic/show?id=59d798e61f0' target=_blank style='color:#2F92EE;'>#雌激素受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98761, encryptionId=59d798e61f0, topicName=雌激素受体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae6c9649886, createdName=surilei, createdTime=Sat Jan 04 02:43:00 CST 2014, time=2014-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584614, encodeId=098d158461402, content=<a href='/topic/show?id=83f5e9250e9' target=_blank style='color:#2F92EE;'>#编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79250, encryptionId=83f5e9250e9, topicName=编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b10a17056098, createdName=12498f6em12暂无昵称, createdTime=Sat Jan 04 02:43:00 CST 2014, time=2014-01-04, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1805909, encodeId=02af180590904, content=<a href='/topic/show?id=c435e92536b' target=_blank style='color:#2F92EE;'>#编码基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79253, encryptionId=c435e92536b, topicName=编码基因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Tue Jun 03 12:43:00 CST 2014, time=2014-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879825, encodeId=c9c118e982504, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Jan 31 09:43:00 CST 2014, time=2014-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733668, encodeId=d0a51e3366847, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Thu Jun 05 23:43:00 CST 2014, time=2014-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685924, encodeId=7379168592419, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Tue Jan 14 20:43:00 CST 2014, time=2014-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048559, encodeId=e841204855970, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Mon Apr 07 15:43:00 CST 2014, time=2014-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=6536, encodeId=4717653690, content=如何临床应用呢, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Sat Jan 04 10:07:00 CST 2014, time=2014-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342290, encodeId=ff051342290e7, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Sat Jan 04 02:43:00 CST 2014, time=2014-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386107, encodeId=13dc138610ef4, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sat Jan 04 02:43:00 CST 2014, time=2014-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503469, encodeId=7bb31503469b0, content=<a href='/topic/show?id=59d798e61f0' target=_blank style='color:#2F92EE;'>#雌激素受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98761, encryptionId=59d798e61f0, topicName=雌激素受体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae6c9649886, createdName=surilei, createdTime=Sat Jan 04 02:43:00 CST 2014, time=2014-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584614, encodeId=098d158461402, content=<a href='/topic/show?id=83f5e9250e9' target=_blank style='color:#2F92EE;'>#编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79250, encryptionId=83f5e9250e9, topicName=编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b10a17056098, createdName=12498f6em12暂无昵称, createdTime=Sat Jan 04 02:43:00 CST 2014, time=2014-01-04, status=1, ipAttribution=)]
    2014-01-31 liye789132251
  3. [GetPortalCommentsPageByObjectIdResponse(id=1805909, encodeId=02af180590904, content=<a href='/topic/show?id=c435e92536b' target=_blank style='color:#2F92EE;'>#编码基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79253, encryptionId=c435e92536b, topicName=编码基因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Tue Jun 03 12:43:00 CST 2014, time=2014-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879825, encodeId=c9c118e982504, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Jan 31 09:43:00 CST 2014, time=2014-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733668, encodeId=d0a51e3366847, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Thu Jun 05 23:43:00 CST 2014, time=2014-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685924, encodeId=7379168592419, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Tue Jan 14 20:43:00 CST 2014, time=2014-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048559, encodeId=e841204855970, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Mon Apr 07 15:43:00 CST 2014, time=2014-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=6536, encodeId=4717653690, content=如何临床应用呢, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Sat Jan 04 10:07:00 CST 2014, time=2014-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342290, encodeId=ff051342290e7, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Sat Jan 04 02:43:00 CST 2014, time=2014-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386107, encodeId=13dc138610ef4, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sat Jan 04 02:43:00 CST 2014, time=2014-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503469, encodeId=7bb31503469b0, content=<a href='/topic/show?id=59d798e61f0' target=_blank style='color:#2F92EE;'>#雌激素受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98761, encryptionId=59d798e61f0, topicName=雌激素受体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae6c9649886, createdName=surilei, createdTime=Sat Jan 04 02:43:00 CST 2014, time=2014-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584614, encodeId=098d158461402, content=<a href='/topic/show?id=83f5e9250e9' target=_blank style='color:#2F92EE;'>#编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79250, encryptionId=83f5e9250e9, topicName=编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b10a17056098, createdName=12498f6em12暂无昵称, createdTime=Sat Jan 04 02:43:00 CST 2014, time=2014-01-04, status=1, ipAttribution=)]
    2014-06-05 canlab
  4. [GetPortalCommentsPageByObjectIdResponse(id=1805909, encodeId=02af180590904, content=<a href='/topic/show?id=c435e92536b' target=_blank style='color:#2F92EE;'>#编码基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79253, encryptionId=c435e92536b, topicName=编码基因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Tue Jun 03 12:43:00 CST 2014, time=2014-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879825, encodeId=c9c118e982504, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Jan 31 09:43:00 CST 2014, time=2014-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733668, encodeId=d0a51e3366847, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Thu Jun 05 23:43:00 CST 2014, time=2014-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685924, encodeId=7379168592419, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Tue Jan 14 20:43:00 CST 2014, time=2014-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048559, encodeId=e841204855970, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Mon Apr 07 15:43:00 CST 2014, time=2014-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=6536, encodeId=4717653690, content=如何临床应用呢, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Sat Jan 04 10:07:00 CST 2014, time=2014-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342290, encodeId=ff051342290e7, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Sat Jan 04 02:43:00 CST 2014, time=2014-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386107, encodeId=13dc138610ef4, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sat Jan 04 02:43:00 CST 2014, time=2014-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503469, encodeId=7bb31503469b0, content=<a href='/topic/show?id=59d798e61f0' target=_blank style='color:#2F92EE;'>#雌激素受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98761, encryptionId=59d798e61f0, topicName=雌激素受体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae6c9649886, createdName=surilei, createdTime=Sat Jan 04 02:43:00 CST 2014, time=2014-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584614, encodeId=098d158461402, content=<a href='/topic/show?id=83f5e9250e9' target=_blank style='color:#2F92EE;'>#编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79250, encryptionId=83f5e9250e9, topicName=编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b10a17056098, createdName=12498f6em12暂无昵称, createdTime=Sat Jan 04 02:43:00 CST 2014, time=2014-01-04, status=1, ipAttribution=)]
    2014-01-14 江川靖瑶
  5. [GetPortalCommentsPageByObjectIdResponse(id=1805909, encodeId=02af180590904, content=<a href='/topic/show?id=c435e92536b' target=_blank style='color:#2F92EE;'>#编码基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79253, encryptionId=c435e92536b, topicName=编码基因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Tue Jun 03 12:43:00 CST 2014, time=2014-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879825, encodeId=c9c118e982504, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Jan 31 09:43:00 CST 2014, time=2014-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733668, encodeId=d0a51e3366847, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Thu Jun 05 23:43:00 CST 2014, time=2014-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685924, encodeId=7379168592419, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Tue Jan 14 20:43:00 CST 2014, time=2014-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048559, encodeId=e841204855970, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Mon Apr 07 15:43:00 CST 2014, time=2014-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=6536, encodeId=4717653690, content=如何临床应用呢, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Sat Jan 04 10:07:00 CST 2014, time=2014-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342290, encodeId=ff051342290e7, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Sat Jan 04 02:43:00 CST 2014, time=2014-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386107, encodeId=13dc138610ef4, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sat Jan 04 02:43:00 CST 2014, time=2014-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503469, encodeId=7bb31503469b0, content=<a href='/topic/show?id=59d798e61f0' target=_blank style='color:#2F92EE;'>#雌激素受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98761, encryptionId=59d798e61f0, topicName=雌激素受体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae6c9649886, createdName=surilei, createdTime=Sat Jan 04 02:43:00 CST 2014, time=2014-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584614, encodeId=098d158461402, content=<a href='/topic/show?id=83f5e9250e9' target=_blank style='color:#2F92EE;'>#编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79250, encryptionId=83f5e9250e9, topicName=编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b10a17056098, createdName=12498f6em12暂无昵称, createdTime=Sat Jan 04 02:43:00 CST 2014, time=2014-01-04, status=1, ipAttribution=)]
    2014-04-07 cy0324
  6. [GetPortalCommentsPageByObjectIdResponse(id=1805909, encodeId=02af180590904, content=<a href='/topic/show?id=c435e92536b' target=_blank style='color:#2F92EE;'>#编码基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79253, encryptionId=c435e92536b, topicName=编码基因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Tue Jun 03 12:43:00 CST 2014, time=2014-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879825, encodeId=c9c118e982504, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Jan 31 09:43:00 CST 2014, time=2014-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733668, encodeId=d0a51e3366847, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Thu Jun 05 23:43:00 CST 2014, time=2014-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685924, encodeId=7379168592419, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Tue Jan 14 20:43:00 CST 2014, time=2014-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048559, encodeId=e841204855970, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Mon Apr 07 15:43:00 CST 2014, time=2014-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=6536, encodeId=4717653690, content=如何临床应用呢, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Sat Jan 04 10:07:00 CST 2014, time=2014-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342290, encodeId=ff051342290e7, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Sat Jan 04 02:43:00 CST 2014, time=2014-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386107, encodeId=13dc138610ef4, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sat Jan 04 02:43:00 CST 2014, time=2014-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503469, encodeId=7bb31503469b0, content=<a href='/topic/show?id=59d798e61f0' target=_blank style='color:#2F92EE;'>#雌激素受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98761, encryptionId=59d798e61f0, topicName=雌激素受体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae6c9649886, createdName=surilei, createdTime=Sat Jan 04 02:43:00 CST 2014, time=2014-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584614, encodeId=098d158461402, content=<a href='/topic/show?id=83f5e9250e9' target=_blank style='color:#2F92EE;'>#编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79250, encryptionId=83f5e9250e9, topicName=编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b10a17056098, createdName=12498f6em12暂无昵称, createdTime=Sat Jan 04 02:43:00 CST 2014, time=2014-01-04, status=1, ipAttribution=)]
    2014-01-04 lovetcm

    如何临床应用呢

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1805909, encodeId=02af180590904, content=<a href='/topic/show?id=c435e92536b' target=_blank style='color:#2F92EE;'>#编码基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79253, encryptionId=c435e92536b, topicName=编码基因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Tue Jun 03 12:43:00 CST 2014, time=2014-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879825, encodeId=c9c118e982504, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Jan 31 09:43:00 CST 2014, time=2014-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733668, encodeId=d0a51e3366847, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Thu Jun 05 23:43:00 CST 2014, time=2014-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685924, encodeId=7379168592419, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Tue Jan 14 20:43:00 CST 2014, time=2014-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048559, encodeId=e841204855970, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Mon Apr 07 15:43:00 CST 2014, time=2014-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=6536, encodeId=4717653690, content=如何临床应用呢, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Sat Jan 04 10:07:00 CST 2014, time=2014-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342290, encodeId=ff051342290e7, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Sat Jan 04 02:43:00 CST 2014, time=2014-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386107, encodeId=13dc138610ef4, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sat Jan 04 02:43:00 CST 2014, time=2014-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503469, encodeId=7bb31503469b0, content=<a href='/topic/show?id=59d798e61f0' target=_blank style='color:#2F92EE;'>#雌激素受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98761, encryptionId=59d798e61f0, topicName=雌激素受体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae6c9649886, createdName=surilei, createdTime=Sat Jan 04 02:43:00 CST 2014, time=2014-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584614, encodeId=098d158461402, content=<a href='/topic/show?id=83f5e9250e9' target=_blank style='color:#2F92EE;'>#编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79250, encryptionId=83f5e9250e9, topicName=编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b10a17056098, createdName=12498f6em12暂无昵称, createdTime=Sat Jan 04 02:43:00 CST 2014, time=2014-01-04, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1805909, encodeId=02af180590904, content=<a href='/topic/show?id=c435e92536b' target=_blank style='color:#2F92EE;'>#编码基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79253, encryptionId=c435e92536b, topicName=编码基因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Tue Jun 03 12:43:00 CST 2014, time=2014-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879825, encodeId=c9c118e982504, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Jan 31 09:43:00 CST 2014, time=2014-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733668, encodeId=d0a51e3366847, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Thu Jun 05 23:43:00 CST 2014, time=2014-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685924, encodeId=7379168592419, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Tue Jan 14 20:43:00 CST 2014, time=2014-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048559, encodeId=e841204855970, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Mon Apr 07 15:43:00 CST 2014, time=2014-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=6536, encodeId=4717653690, content=如何临床应用呢, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Sat Jan 04 10:07:00 CST 2014, time=2014-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342290, encodeId=ff051342290e7, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Sat Jan 04 02:43:00 CST 2014, time=2014-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386107, encodeId=13dc138610ef4, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sat Jan 04 02:43:00 CST 2014, time=2014-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503469, encodeId=7bb31503469b0, content=<a href='/topic/show?id=59d798e61f0' target=_blank style='color:#2F92EE;'>#雌激素受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98761, encryptionId=59d798e61f0, topicName=雌激素受体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae6c9649886, createdName=surilei, createdTime=Sat Jan 04 02:43:00 CST 2014, time=2014-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584614, encodeId=098d158461402, content=<a href='/topic/show?id=83f5e9250e9' target=_blank style='color:#2F92EE;'>#编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79250, encryptionId=83f5e9250e9, topicName=编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b10a17056098, createdName=12498f6em12暂无昵称, createdTime=Sat Jan 04 02:43:00 CST 2014, time=2014-01-04, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=1805909, encodeId=02af180590904, content=<a href='/topic/show?id=c435e92536b' target=_blank style='color:#2F92EE;'>#编码基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79253, encryptionId=c435e92536b, topicName=编码基因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Tue Jun 03 12:43:00 CST 2014, time=2014-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879825, encodeId=c9c118e982504, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Jan 31 09:43:00 CST 2014, time=2014-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733668, encodeId=d0a51e3366847, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Thu Jun 05 23:43:00 CST 2014, time=2014-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685924, encodeId=7379168592419, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Tue Jan 14 20:43:00 CST 2014, time=2014-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048559, encodeId=e841204855970, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Mon Apr 07 15:43:00 CST 2014, time=2014-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=6536, encodeId=4717653690, content=如何临床应用呢, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Sat Jan 04 10:07:00 CST 2014, time=2014-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342290, encodeId=ff051342290e7, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Sat Jan 04 02:43:00 CST 2014, time=2014-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386107, encodeId=13dc138610ef4, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sat Jan 04 02:43:00 CST 2014, time=2014-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503469, encodeId=7bb31503469b0, content=<a href='/topic/show?id=59d798e61f0' target=_blank style='color:#2F92EE;'>#雌激素受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98761, encryptionId=59d798e61f0, topicName=雌激素受体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae6c9649886, createdName=surilei, createdTime=Sat Jan 04 02:43:00 CST 2014, time=2014-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584614, encodeId=098d158461402, content=<a href='/topic/show?id=83f5e9250e9' target=_blank style='color:#2F92EE;'>#编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79250, encryptionId=83f5e9250e9, topicName=编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b10a17056098, createdName=12498f6em12暂无昵称, createdTime=Sat Jan 04 02:43:00 CST 2014, time=2014-01-04, status=1, ipAttribution=)]
  10. [GetPortalCommentsPageByObjectIdResponse(id=1805909, encodeId=02af180590904, content=<a href='/topic/show?id=c435e92536b' target=_blank style='color:#2F92EE;'>#编码基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79253, encryptionId=c435e92536b, topicName=编码基因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Tue Jun 03 12:43:00 CST 2014, time=2014-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879825, encodeId=c9c118e982504, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Jan 31 09:43:00 CST 2014, time=2014-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733668, encodeId=d0a51e3366847, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Thu Jun 05 23:43:00 CST 2014, time=2014-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685924, encodeId=7379168592419, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Tue Jan 14 20:43:00 CST 2014, time=2014-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048559, encodeId=e841204855970, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Mon Apr 07 15:43:00 CST 2014, time=2014-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=6536, encodeId=4717653690, content=如何临床应用呢, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Sat Jan 04 10:07:00 CST 2014, time=2014-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342290, encodeId=ff051342290e7, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Sat Jan 04 02:43:00 CST 2014, time=2014-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386107, encodeId=13dc138610ef4, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sat Jan 04 02:43:00 CST 2014, time=2014-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503469, encodeId=7bb31503469b0, content=<a href='/topic/show?id=59d798e61f0' target=_blank style='color:#2F92EE;'>#雌激素受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98761, encryptionId=59d798e61f0, topicName=雌激素受体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae6c9649886, createdName=surilei, createdTime=Sat Jan 04 02:43:00 CST 2014, time=2014-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584614, encodeId=098d158461402, content=<a href='/topic/show?id=83f5e9250e9' target=_blank style='color:#2F92EE;'>#编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79250, encryptionId=83f5e9250e9, topicName=编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b10a17056098, createdName=12498f6em12暂无昵称, createdTime=Sat Jan 04 02:43:00 CST 2014, time=2014-01-04, status=1, ipAttribution=)]

相关资讯

Mol Cell:长片段非编码RNA促进肿瘤生长机制

从中国科学技术大学获悉,该校生命科学学院吴缅和梅一德教授研究组,揭示了长片段非编码RNA通过调控肿瘤细胞瓦伯格效应促进肿瘤生长的机制。相关研究近日在线发表在国际著名学术期刊《细胞》子刊《分子细胞》。 肿瘤细胞即使在有氧状态下也优先进行糖酵解,而不是通过产能效率更高的氧化磷酸化途径为细胞生长提供能量,这就是瓦伯格效应。低氧微环境下,肿瘤细胞也能促进瓦伯格效应,但具体的分

Cancer Res:研究人员确认恶性生殖细胞肿瘤分子开关

最近,英国剑桥大学研究人员称,一种名为LIN28的蛋白在恶性生殖细胞肿瘤的形成过程中起着重要作用,是促发癌症的关键“开关”。这一发现对于开发新的恶性生殖细胞肿瘤治疗方法具有重要意义。 恶性生殖细胞肿瘤是一种各个年龄段男女都可能罹患的癌症,如睾丸癌、卵巢癌皆属于此列。虽然目前的化疗疗法可在一定程度上治疗该类疾病,但化疗产生的副作用也很严重,会损害患者的听力,造成肾脏、肺

Cancer Res:郑州大学发表癌症新文章

来自郑州大学、中山大学癌症中心及新加坡国立大学等处的研究人员证实,在食管鳞状细胞癌(Esophageal Squamous Cell Carcinoma,ESCC)中腺苷脱氨酶ADARs介导了腺苷(A)至肌苷(I)RNA编辑。这一研究发现发表在12月的《癌症研究》(Cancer research)杂志上。 【原文下载】郑州大学第一附属医院肿瘤科的秦艳茹(Yan-R

Cancer Res:研究发现TRAF6促进癌症发展机制

近日,中科院上海生科院营养科学研究所的科学家在一项研究中,揭示了TRAF6在癌症发生发展中新的功能和机制。相关研究成果日前发表于美国《癌症研究》杂志。 肿瘤坏死因子受体相关因子6(TRAF6),是肿瘤坏死因子受体相关因子家族的成员之一,最初被发现于白细胞介素1(IL-1)及CD40信号传导途径。作为泛素连接酶,TRAF6可以对其底物进行Lys63连接的多聚泛素化修饰,进而促进其底物激酶如TAK1

JNS:新手术法可摘除脑部深处肿瘤

颅咽管瘤是一种发生于脑内深部的常见先天性肿瘤。虽然它是良性肿瘤,但是如果体积达到一定程度,就会导致失明和认知能力降低。日本大阪市立大学的研究小组开发出了一种新手术方法,通过切开耳后的骨骼来摘除颅咽管瘤,成功地将10年后的复发率控制在15%以下。 日本全国每年约有700人患颅咽管瘤,以前,一般都是切开眼球中间或者是额角骨骼以摘除肿瘤,但是由于颅咽管瘤会围绕视神经和脑深部

Molecular Therapy:用“细菌车”运送抗癌“弹药”摧毁肿瘤

把肿瘤的治疗基因“搭载”到减毒化的鼠伤寒沙门氏菌,靶送至肿瘤细胞,可显著抑制原发性肿瘤(结肠、肝)和肺转移瘤。海口市人民医院核医学科负责人姜圣男博士,在2013年11期《自然》(Nature)旗下的《分子治疗》杂志(Molecular therapy),发表的题为《 以基因重组细菌为载体靶向给抗癌药过程可视化研究》,揭示了这种靶向治疗肿瘤的新方法。这篇论文该被该期刊评为当期